Dissolvable tablets don’t work for people with severe allergies to grass pollen
It’s summertime and—if you’re in Eugene, Oregon—the livin’ is sneezy. Eugene is the nation’s top spot for allergies this week according to IMS Health, a health information company that provides allergy alerts for cities across the nation. Eugene residents can blame their runny noses and itchy eyes on the city’s abundant grasses, which are currently spewing high levels of pollen into the air.
Eugene is just the tip of the allergy iceberg. If you live near a patch of green, you routinely inhale pollen. You’re in good company if your body reacts to it. More than 50 million Americans hav...
Source: New Harvard Health Information - July 2, 2015 Category: Consumer Health News Authors: Beverly Merz Tags: Asthma and Allergies dissolvable tablets grass pollen allergies Source Type: news
Adding a LAMA to Salmeterol/Fluticasone Improves COPD Lung FunctionAdding a LAMA to Salmeterol/Fluticasone Improves COPD Lung Function
Adding a once-a-day long-acting muscarinic antagonist (LAMA) to salmeterol/fluticasone propionate (SAL/FP) improves outcomes in chronic obstructive pulmonary disease (COPD), according to a report from Australia and New Zealand. Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - May 8, 2015 Category: Consumer Health News Tags: Pulmonary Medicine News Source Type: news
Breo Ellipta Approved for Asthma (FREE)
By the Editors
The FDA has approved fluticasone furoate/vilanterol (Breo Ellipta) for use in adults who have severe asthma or asthma that is not … (Source: Physician's First Watch current issue)
Source: Physician's First Watch current issue - May 4, 2015 Category: Primary Care Source Type: news
FDA Okays Breo Ellipta for Asthma in AdultsFDA Okays Breo Ellipta for Asthma in Adults
The once-daily treatment combines the inhaled corticosteroid fluticasone furoate and the long-acting beta2-agonist vilanterol. FDA Approvals (Source: Medscape FamilyMedicine Headlines)
Source: Medscape FamilyMedicine Headlines - May 1, 2015 Category: Primary Care Tags: Pulmonary Medicine News Alert Source Type: news
GSK and Theravance receive FDA approval for asthma drug Breo Ellipta
GlaxoSmithKline (GSK) and Theravance have received approval from the US Food and Drug Administration (FDA) for the Breo Ellipta (fluticasone furoate/vilanterol [FF/VI]) as the once-daily treatment for asthma patients aged 18 years and older. (Source: Pharmaceutical Technology)
Source: Pharmaceutical Technology - April 30, 2015 Category: Pharmaceuticals Source Type: news
azelastine hydrochloride and fluticasone propionate (Dymista)
Title: azelastine hydrochloride and fluticasone propionate (Dymista)Category: MedicationsCreated: 4/20/2015 12:00:00 AMLast Editorial Review: 4/20/2015 12:00:00 AM (Source: MedicineNet Allergies General)
Source: MedicineNet Allergies General - April 20, 2015 Category: Allergy & Immunology Source Type: news
fluticasone (Flonase, Flonase Allergy Relief)
Title: fluticasone (Flonase, Flonase Allergy Relief)Category: MedicationsCreated: 3/26/1998 12:00:00 AMLast Editorial Review: 4/14/2015 12:00:00 AM (Source: MedicineNet Allergies General)
Source: MedicineNet Allergies General - April 14, 2015 Category: Allergy & Immunology Source Type: news
fluticasone (Flonase)
Title: fluticasone (Flonase)Category: MedicationsCreated: 3/26/1998 12:00:00 AMLast Editorial Review: 2/20/2015 12:00:00 AM (Source: MedicineNet Allergies General)
Source: MedicineNet Allergies General - February 20, 2015 Category: Allergy & Immunology Source Type: news
Lupin and Celon Pharma partner for generic version of GSK’s Advair Diskus
India-based drugmaker Lupin has signed an agreement with Polish biopharmaceutical firm Celon Pharma to develop a fluticasone / salmeterol dry powder inhaler (DPI). (Source: Pharmaceutical Technology)
Source: Pharmaceutical Technology - February 18, 2015 Category: Pharmaceuticals Source Type: news
Is A Specific Corticosteroid Better for Treatment of Asthma Than Another?
Discussion
Asthma is a chronic obstructive lung disease that affects many children and adults. There is a wide range of symptoms that people experience from occurring relatively rarely (ie intermittent asthma) to patients having daily symptoms of such intensity that they are life-threatening (ie chronic severe asthma). The goals of asthma management include patient education and medication management so patients have no or minimal symptoms, prevent exacerbations, have no activity restrictions, have normal pulmonary function tests, have no or minimal medication side effects and meet patient and family expectations. Well con...
Source: PediatricEducation.org - January 5, 2015 Category: Pediatrics Authors: pediatriceducationmin Tags: Uncategorized Source Type: news
Triple Therapy Tied to Reduced Rate of COPD Exacerbations
Benefits seen for triple therapy with fluticasone furoate, umeclidinium, and vilanterol (Source: Pulmonary Medicine News - Doctors Lounge)
Source: Pulmonary Medicine News - Doctors Lounge - November 11, 2014 Category: Respiratory Medicine Tags: Family Medicine, Internal Medicine, Emergency Medicine, Nursing, Pharmacy, Pulmonology, Journal, Source Type: news
Fluticasone Furoate for Asthma in Adults and AdolescentsFluticasone Furoate for Asthma in Adults and Adolescents
Inhaled corticosteroids are a mainstay of therapy for persistent asthma, but suboptimal adherence with twice-daily use is widespread. BMC Pulmonary Medicine (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - October 3, 2014 Category: Consumer Health News Tags: Pulmonary Medicine Journal Article Source Type: news
Mundipharma reports Phase III flutiform trial results in paediatric asthma
Mundipharma has reported results from a randomised, multicentre, Phase III trial of flutiform, a combination of fluticasone propionate and formoterol in a single pressurised metered dose inhaler, to treat paediatric asthma. (Source: Drug Development Technology)
Source: Drug Development Technology - September 8, 2014 Category: Pharmaceuticals Source Type: news
Novartis data show once-daily Ultibro® Breezhaler® is superior in COPD
Novartis presented new data that demonstrated once-daily Ultibro® Breezhaler® (indacaterol/glycopyrronium bromide) was superior in reducing exacerbations (flare ups) and improving lung function compared to twice-daily Seretide®Accuhaler®* (salmeterol/fluticasone (SFC)), in patients with moderate-to-severe chronic obstructive pulmonary disease (COPD). (Source: Pharmacy Europe)
Source: Pharmacy Europe - September 8, 2014 Category: Drugs & Pharmacology Authors: Annabel De Coster Tags: *** Editor's Pick Industry News Respiratory copd exacerbation indacaterol/glycopyrronium bromide Latest News lung function Source Type: news
Cipla introduces Serroflo for respiratory treatment in Germany and Sweden
India-based Cipla has introduced Serroflo (salmeterol/fluticasone MDI) in Germany and Sweden to treat patients suffering from asthma. (Source: Pharmaceutical Technology)
Source: Pharmaceutical Technology - September 2, 2014 Category: Pharmaceuticals Source Type: news
